This site contains promotional content intended for Healthcare Professionals in Ireland and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Area

Beyonttra
®
▼(acoramidis)

Safety Profile

Adverse reactions as per SmPC:

Gastrointestinal Disorders - Diarrhoea:

Very common (≥1 in 10)

Diarrhoea was reported in 11.6 % of participants in the BEYONTTRA group compared with 7.6 % in the placebo group. The majority of events of diarrhoea were categorised as mild and resolved.

Metabolism & nutrition disorders - Gout:

Very Common (≥1 in 10) 

Gout was reported in 11.2 % of participants in the BEYONTTRA group compared with 8.1 % in the placebo group. The majority of events of gout were categorised as mild to moderate and resolved.

This product is subject to additional monitoring.

Please refer to the full IE Summary of Product Characteristics (SmPC) for detailed safety warnings and information.
About Beyonttra®▼ (acoramidis)
Learn more about Beyonttra® (acoramidis).
PP-BEY-IE-0031-1, November 2025
Beyonttra®▼ (acoramidis) - Dosing
Learn more about the Dosing of Beyonttra® (acoramidis).
PP-BEY-IE-0032-1, November 2025
Beyonttra®▼ (acoramidis) - ATTRibute-CM Study Design
Explore more about the ATTRibute-CM Study Design of evaluating the efficacy & safety of acoramidis vs placebo.
PP-BEY-IE-0036-1, November 2025

PP-BEY-IE-0033-1   |   November 2025

 

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professional are asked to report any suspected adverse reactions.